Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246))

F. Navid; S. D. Baker; M. B. McCarville; C. F. Stewart; C. A. Billups; J. Wu

doi:10.1158/1078-0432.CCR-13-0503

Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246))

F. Navid, S. D. Baker, M. B. McCarville, C. F. Stewart, C. A. Billups, J. Wu

Internal Medicine

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	1914
Number of pages	1
Journal	Clinical Cancer Research
Volume	19
Issue number	7
DOIs	https://doi.org/10.1158/1078-0432.CCR-13-0503
State	Published - Apr 1 2013

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-13-0503

Fingerprint

Dive into the research topics of 'Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246))'. Together they form a unique fingerprint.

Cite this

Navid, F., Baker, S. D., McCarville, M. B., Stewart, C. F., Billups, C. A., & Wu, J. (2013). Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246)). Clinical Cancer Research, 19(7), 1914. https://doi.org/10.1158/1078-0432.CCR-13-0503

@article{9f9c8a543e0f496ca7eaa861f0133f50,

title = "Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246))",

author = "F. Navid and Baker, {S. D.} and McCarville, {M. B.} and Stewart, {C. F.} and Billups, {C. A.} and J. Wu",

year = "2013",

month = apr,

day = "1",

doi = "10.1158/1078-0432.CCR-13-0503",

language = "English",

volume = "19",

pages = "1914",

number = "7",

}

Navid, F, Baker, SD, McCarville, MB, Stewart, CF, Billups, CA & Wu, J 2013, 'Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246))', Clinical Cancer Research, vol. 19, no. 7, pp. 1914. https://doi.org/10.1158/1078-0432.CCR-13-0503

Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246)). / Navid, F.; Baker, S. D.; McCarville, M. B. et al.
In: Clinical Cancer Research, Vol. 19, No. 7, 01.04.2013, p. 1914.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246))

AU - Navid, F.

AU - Baker, S. D.

AU - McCarville, M. B.

AU - Stewart, C. F.

AU - Billups, C. A.

AU - Wu, J.

PY - 2013/4/1

Y1 - 2013/4/1

UR - http://www.scopus.com/inward/record.url?scp=84877089236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877089236&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-0503

DO - 10.1158/1078-0432.CCR-13-0503

M3 - Comment/debate

AN - SCOPUS:84877089236

SN - 1078-0432

VL - 19

SP - 1914

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -

Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J. Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246)). Clinical Cancer Research. 2013 Apr 1;19(7):1914. doi: 10.1158/1078-0432.CCR-13-0503

Correction: Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumorsIn this article (Clinical Cancer Research (2013) 19, 1, (236-246))

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this